Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects

Annals of Allergy, Asthma and Immunology

Volumn 76, Issue 5, 1996, Pages 476-

  Hey, J A ^a   Del Prado, M ^a   Egan, R W ^a   Kreutner, W ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; EBASTINE; LORATADINE; TERFENADINE;

ANIMAL MODEL; ARRHYTHMOGENESIS; CARDIOTOXICITY; CONTROLLED STUDY; ELECTROCARDIOGRAM; GUINEA PIG; HEART ARRHYTHMIA; INTRAVENOUS DRUG ADMINISTRATION; LETTER; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL;

EID: 0029925455     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63468-0     Document Type: Letter

References (4)

1. 1-Receptor antagonists; comparative tolerability and safety Drug Safety 10 5 1994 35 80
2. RL Woolsey Y Chan JP Frieman RA Gillis Mechanism of cardiotoxic actions of terfenadine JAMA 269 1993 1532 1536
3. CI Berul M Morad Regulation of potassium channels by nonsedating antihistamines Circulation 91 1995 2220 2225
4. 1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea-pigs Clin Exp Allergy 25 1995 974 984